1 |
CSF1R
| 9件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Osteoclast differentiation, Hematopoietic cell lineage, Pathways in cancer, Transcriptional misregulation in cancer | D08552
D08552
|
Sunitinib
| 2件: 28 28, 34 |
2 |
CSF1R
| 9件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Osteoclast differentiation, Hematopoietic cell lineage, Pathways in cancer, Transcriptional misregulation in cancer | D11270
D11270
|
Pexidartinib
| 1件: 34 34 |
3 |
CSF2
| 11件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Shigellosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Transcriptional misregulation in cancer, Rheumatoid arthritis | D11343
D11343
|
Otilimab
| 1件: 46 46 |
4 |
CSF2RA
| 3件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D05066
D05066
|
Molgramostim
| 3件: 97 97, 229, 299 |
5 |
CSF2RA
| 3件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D05712
D05712
|
Regramostim
| 1件: 229 229 |
6 |
CSF2RA
| 3件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D05803
D05803
|
Sargramostim
| 7件: 6 6, 28, 60, 62, 96, 229, 285 |
7 |
CSF2RA
| 3件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D09930
D09930
|
Mavrilimumab
| 2件: 41 41, 46 |
8 |
CSF3R
| 4件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D03235
D03235
|
Filgrastim
| 35件: 2 2, 6, 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 |
9 |
CSF3R
| 4件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D03247
D03247
|
Lenograstim
| 7件: 2 2, 13, 16, 18, 19, 57, 65 |
10 |
CSF3R
| 4件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D06889
D06889
|
Pegfilgrastim
| 1件: 60 60 |
11 |
EPOR
| 4件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D09946
D09946
|
Peginesatide
| 1件: 283 283 |
12 |
FLT3
| 6件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Pathways in cancer, Transcriptional misregulation in cancer | D08524
D08524
|
Sorafenib
| 2件: 34 34, 86 |
13 |
FLT3
| 6件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Pathways in cancer, Transcriptional misregulation in cancer | D08552
D08552
|
Sunitinib
| 2件: 28 28, 34 |
14 |
FLT3
| 6件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Pathways in cancer, Transcriptional misregulation in cancer | D11270
D11270
|
Pexidartinib
| 1件: 34 34 |
15 |
ANPEP
| 3件: Metabolic pathways Metabolic pathways, Renin-angiotensin system, Hematopoietic cell lineage | D00087
D00087
|
Ubenimex
| 1件: 86 86 |
16 |
IL1A
| 15件: MAPK signaling pathway MAPK signaling pathway, Necroptosis, Osteoclast differentiation, Hematopoietic cell lineage, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Leishmaniasis, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
17 |
IL1A
| 15件: MAPK signaling pathway MAPK signaling pathway, Necroptosis, Osteoclast differentiation, Hematopoietic cell lineage, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Leishmaniasis, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis | D06635
D06635
|
Rilonacept
| 4件: 51 51, 106, 107, 266 |
18 |
IL1A
| 15件: MAPK signaling pathway MAPK signaling pathway, Necroptosis, Osteoclast differentiation, Hematopoietic cell lineage, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Leishmaniasis, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis | D11253
D11253
|
Bermekimab
| 1件: 51 51 |
19 |
IL1B
| 31件: MAPK signaling pathway MAPK signaling pathway, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Inflammatory bowel disease, Rheumatoid arthritis, Lipid and atherosclerosis | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
20 |
IL1B
| 31件: MAPK signaling pathway MAPK signaling pathway, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Inflammatory bowel disease, Rheumatoid arthritis, Lipid and atherosclerosis | D06635
D06635
|
Rilonacept
| 4件: 51 51, 106, 107, 266 |
21 |
IL1B
| 31件: MAPK signaling pathway MAPK signaling pathway, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Inflammatory bowel disease, Rheumatoid arthritis, Lipid and atherosclerosis | D09315
D09315
|
Canakinumab
| 10件: 46 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 |
22 |
IL1B
| 31件: MAPK signaling pathway MAPK signaling pathway, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Inflammatory bowel disease, Rheumatoid arthritis, Lipid and atherosclerosis | D09911
D09911
|
Gevokizumab
| 4件: 41 41, 50, 56, 269 |
23 |
IL1R1
| 10件: MAPK signaling pathway MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Hematopoietic cell lineage, Th17 cell differentiation, Inflammatory mediator regulation of TRP channels, Pathogenic Escherichia coli infection, Shigellosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection | D02934
D02934
|
Anakinra
| 18件: 2 2, 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 |
24 |
IL2RA
| 9件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer | D00748
D00748
|
Aldesleukin
| 6件: 2 2, 35, 49, 65, 96, 97 |
25 |
IL2RA
| 9件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer | D03058
D03058
|
Basiliximab
| 6件: 2 2, 50, 66, 97, 222, 228 |
26 |
IL2RA
| 9件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer | D03639
D03639
|
Daclizumab
| 8件: 13 13, 56, 60, 65, 97, 107, 283, 284 |
27 |
IL4
| 11件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Intestinal immune network for IgA production, Leishmaniasis, Pathways in cancer, Inflammatory bowel disease | D03117
D03117
|
Binetrakin
| 1件: 46 46 |
28 |
IL4R
| 7件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Pathways in cancer, Inflammatory bowel disease | D10354
D10354
|
Dupilumab
| 5件: 51 51, 97, 98, 160, 162 |
29 |
IL5
| 8件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th1 and Th2 cell differentiation, T cell receptor signaling pathway, Intestinal immune network for IgA production, Pathways in cancer, Inflammatory bowel disease | D04923
D04923
|
Mepolizumab
| 4件: 44 44, 45, 98, 162 |
30 |
IL5
| 8件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th1 and Th2 cell differentiation, T cell receptor signaling pathway, Intestinal immune network for IgA production, Pathways in cancer, Inflammatory bowel disease | D08985
D08985
|
Reslizumab
| 2件: 44 44, 98 |
31 |
IL5RA
| 3件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D09874
D09874
|
Benralizumab
| 5件: 44 44, 45, 98, 162, 299 |
32 |
IL6
| 35件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
33 |
IL6
| 35件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D08976
D08976
|
Pomalidomide
| 5件: 28 28, 51, 85, 227, 331 |
34 |
IL6
| 35件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D09669
D09669
|
Siltuximab
| 2件: 28 28, 331 |
35 |
IL6
| 35件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D10080
D10080
|
Sirukumab
| 2件: 41 41, 46 |
36 |
IL6
| 35件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D12487
D12487
|
Olokizumab
| 2件: 46 46, 96 |
37 |
IL6R
| 9件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Pathways in cancer | D02596
D02596
|
Tocilizumab
| 21件: 2 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 |
38 |
IL6R
| 9件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Pathways in cancer | D10161
D10161
|
Sarilumab
| 5件: 41 41, 46, 84, 107, 271 |
39 |
IL6R
| 9件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Pathways in cancer | D11079
D11079
|
Satralizumab
| 3件: 11 11, 13, 86 |
40 |
IL11RA
| 2件: JAK-STAT signaling pathway JAK-STAT signaling pathway, Hematopoietic cell lineage | D05266
D05266
|
Oprelvekin
| 2件: 96 96, 288 |
41 |
ITGA4
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy | D06590
D06590
|
Firategrast
| 1件: 13 13 |
42 |
ITGA4
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy | D06886
D06886
|
Natalizumab
| 6件: 13 13, 15, 25, 46, 63, 96 |
43 |
ITGA4
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy | D08083
D08083
|
Vedolizumab
| 3件: 94 94, 96, 97 |
44 |
ITGA4
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy | D10540
D10540
|
Abrilumab
| 2件: 96 96, 97 |
45 |
KIT
| 8件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer | D03658
D03658
|
Dasatinib
| 2件: 51 51, 85 |
46 |
KIT
| 8件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer | D06414
D06414
|
Dasatinib
| 2件: 51 51, 85 |
47 |
KIT
| 8件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer | D08066
D08066
|
Imatinib
| 12件: 13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 |
48 |
KIT
| 8件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer | D08524
D08524
|
Sorafenib
| 2件: 34 34, 86 |
49 |
KIT
| 8件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer | D08552
D08552
|
Sunitinib
| 2件: 28 28, 34 |
50 |
KIT
| 8件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer | D08953
D08953
|
Nilotinib
| 5件: 6 6, 8, 34, 51, 86 |
51 |
KIT
| 8件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer | D10229
D10229
|
Masitinib
| 6件: 2 2, 5, 6, 13, 46, 96 |
52 |
KIT
| 8件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer | D11270
D11270
|
Pexidartinib
| 1件: 34 34 |
53 |
MME
| 3件: Renin-angiotensin system Renin-angiotensin system, Hematopoietic cell lineage, Protein digestion and absorption | D10225
D10225
|
Sacubitril
| 2件: 58 58, 222 |
54 |
TFRC
| 3件: HIF-1 signaling pathway HIF-1 signaling pathway, Phagosome, Hematopoietic cell lineage | D11812
D11812
|
Pabinafusp alfa
| 1件: 19 19 |
55 |
TNF
| 46件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D00742
D00742
|
Etanercept
| 16件: 15 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285 |
56 |
TNF
| 46件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D00754
D00754
|
Thalidomide
| 20件: 2 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 |
57 |
TNF
| 46件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
58 |
TNF
| 46件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D02597
D02597
|
Adalimumab
| 17件: 19 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 |
59 |
TNF
| 46件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D02598
D02598
|
Infliximab
| 27件: 35 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 |
60 |
TNF
| 46件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D03441
D03441
|
Certolizumab pegol
| 8件: 37 37, 46, 49, 96, 97, 107, 226, 271 |
61 |
TNF
| 46件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D04358
D04358
|
Golimumab
| 8件: 46 46, 56, 84, 96, 97, 107, 270, 271 |
62 |
TNF
| 46件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D04687
D04687
|
Lenalidomide
| 8件: 16 16, 26, 28, 34, 49, 284, 300, 331 |
63 |
TNF
| 46件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D05393
D05393
|
Pegsunercept
| 1件: 46 46 |
64 |
TNF
| 46件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D08976
D08976
|
Pomalidomide
| 5件: 28 28, 51, 85, 227, 331 |
65 |
TNF
| 46件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D09944
D09944
|
Ozoralizumab
| 1件: 46 46 |
66 |
IL1R2
| 4件: Hematopoietic cell lineage Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Transcriptional misregulation in cancer, Prostate cancer | D02934
D02934
|
Anakinra
| 18件: 2 2, 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 |
67 |
CD3D
| 9件: Hematopoietic cell lineage Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | D06314
D06314
|
Visilizumab
| 2件: 96 96, 97 |
68 |
CD3D
| 9件: Hematopoietic cell lineage Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | D08959
D08959
|
Otelixizumab
| 1件: 46 46 |
69 |
CD3E
| 9件: Hematopoietic cell lineage Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | D06314
D06314
|
Visilizumab
| 2件: 96 96, 97 |
70 |
CD3E
| 9件: Hematopoietic cell lineage Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | D08959
D08959
|
Otelixizumab
| 1件: 46 46 |
71 |
CD3E
| 9件: Hematopoietic cell lineage Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | D11463
D11463
|
Mosunetuzumab
| 1件: 49 49 |
72 |
CD3G
| 8件: Hematopoietic cell lineage Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer | D06314
D06314
|
Visilizumab
| 2件: 96 96, 97 |
73 |
CD3G
| 8件: Hematopoietic cell lineage Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08959
D08959
|
Otelixizumab
| 1件: 46 46 |
74 |
CD4
| 11件: Viral life cycle - HIV-1 Viral life cycle - HIV-1, Virion - Human immunodeficiency virus, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Yersinia infection, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | D06356
D06356
|
Zanolimumab
| 1件: 46 46 |
75 |
CD19
| 3件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Hematopoietic cell lineage, Primary immunodeficiency | D11496
D11496
|
Obexelimab
| 1件: 300 300 |
76 |
CD19
| 3件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Hematopoietic cell lineage, Primary immunodeficiency | D11757
D11757
|
Inebilizumab
| 4件: 11 11, 13, 51, 300 |
77 |
MS4A1
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage | D02994
D02994
|
Rituximab
| 48件: 11 11, 13, 14, 19, 26, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 |
78 |
MS4A1
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage | D05218
D05218
|
Ocrelizumab
| 3件: 13 13, 46, 49 |
79 |
MS4A1
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage | D09031
D09031
|
Veltuzumab
| 1件: 46 46 |
80 |
MS4A1
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage | D09314
D09314
|
Ofatumumab
| 3件: 13 13, 35, 46 |
81 |
MS4A1
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage | D09321
D09321
|
Obinutuzumab
| 4件: 43 43, 44, 49, 222 |
82 |
MS4A1
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage | D11243
D11243
|
Ublituximab
| 1件: 13 13 |
83 |
MS4A1
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage | D11463
D11463
|
Mosunetuzumab
| 1件: 49 49 |
84 |
CD22
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage | D04036
D04036
|
Epratuzumab
| 1件: 49 49 |
85 |
CD38
| 6件: Nicotinate and nicotinamide metabolism Nicotinate and nicotinamide metabolism, Metabolic pathways, Hematopoietic cell lineage, Oxytocin signaling pathway, Salivary secretion, Pancreatic secretion | D10777
D10777
|
Daratumumab
| 5件: 13 13, 28, 48, 49, 63 |
86 |
CD38
| 6件: Nicotinate and nicotinamide metabolism Nicotinate and nicotinamide metabolism, Metabolic pathways, Hematopoietic cell lineage, Oxytocin signaling pathway, Salivary secretion, Pancreatic secretion | D11050
D11050
|
Isatuximab
| 3件: 28 28, 61, 283 |
87 |
CD38
| 6件: Nicotinate and nicotinamide metabolism Nicotinate and nicotinamide metabolism, Metabolic pathways, Hematopoietic cell lineage, Oxytocin signaling pathway, Salivary secretion, Pancreatic secretion | D11945
D11945
|
Mezagitamab
| 2件: 63 63, 66 |